Respiratory syncytial virus vaccine

Kathryn Dzintars, Pharm.D., BCPS

VACCINE TYPE

  • Abrysvo is a bivalent respiratory syncytial virus (RSV) prefusion F vaccine and is indicated for:
    • Active immunization of pregnant individuals from 32- to 36-weeks gestation for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth through 6 months of age.
    • Active immunization to prevent LRTD caused by RSV in individuals 60 years of age and older.
    • Supplied as a vial of lyophilized antigen component with a prefilled sterile water syringe for diluent.
  • Arexvy is an adjuvanted RSV vaccine indicated for active immunization to prevent LRTD caused by respiratory syncytial virus (RSV; subtypes A and B) in individuals 60 and older.
    • Supplied as a single-dose vial of lyophilized antigen (RSVPreF3) with an accompanying adjuvant (AS01E) suspension for reconstitution.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: January 7, 2024